# Intranasal lipid carrier cannabidiol for Dravet and Lennox-Gastaut syndromes remains promising but unproven > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-intranasal-lipid-carrier-cannabidio-2026-09-21/ > **Published:** 2026-09-21T22:43:07-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:33:18-04:00 > **Clinical Summary:** medical cannabis research: Physician review of Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: brid... --- CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: bridging preclinical promise to clinical translation. Clinical Insight | CED Clinic This paper addresses a real therapeutic problem: oral pharmaceutical CBD can reduce seizures in Dravet syndrome and Lennox-Gastaut syndrome, yet it is limited by variable absorption, delayed onset, hepatic metabolism, gastrointestinal adverse effects, somnolence, and clinically important drug interactions, especially with clobazam and valproate. Intranasal nanostructured lipid carriers are proposed as a brain-targeted delivery strategy that might raise central nervous system exposure while lowering systemic exposure. Clinically, however, this is still a translation story, not a prescribing story. The review summarizes preclinical pharmacokinetic and seizure-model findings, but does not provide pediatric DS or LGS efficacy, safety, dose-ranging, or long-term neurodevelopmental data. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: Intranasal lipid carrier cannabidiol for Dravet an. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42751849/) A new review argues that intranasal nanostructured lipid carrier CBD could improve brain delivery for severe pediatric epilepsies, but the evidence remains preclinical and not yet patient-ready. What This Study Teaches Us This is a review, not a human efficacy trial: it enrolled 0 patients and reports no pediatric DS or LGS seizure endpoints, responder rates, or risk ratios. It summarizes preclinical data indicating that intranasal NLC-CBD can increase brain-to-plasma CBD ratios, prolong central exposure, and show anticonvulsant effects in animal seizure models such as pentylenetetrazol-induced convulsions. Why This Matters If the delivery strategy translates, it could potentially reduce the oral CBD limitations that matter in practice: slow absorption, variable bioavailability, gastrointestinal adverse effects, liver enzyme concerns, and drug interactions. For now, it mainly helps clinicians explain why formulation science matters and why families should wait for controlled pediatric data. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceTherapeutic deliveryPublication Date2026Sep17Evidence LevelJournal Article, ReviewFocus AreaIntranasal lipid carrier cannabidiol for Dravet and Lennox-GLead AuthorsYashika, Sachin Yadav, Anish Arora, Nisha Bharti et al.DOI10.1080/20415990.2026.2731738PMIDPMID: 42751849 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** A CBD nose spray could soon transform seizure control for children with Dravet and Lennox-Gastaut syndromes. **Primary Journal Data:** The publication is a narrative review of CBD, nanostructured lipid carriers, intranasal delivery, DS, and LGS literature through March 2026. It reports preclinical signals including higher brain targeting, increased brain-to-plasma ratios, longer central exposure, and anticonvulsant effects in animal seizure models, but no completed pediatric DS or LGS clinical trial of intranasal NLC-CBD. **Dr. Caplan’s Clinical Verdict:** Promising delivery science, not clinical proof. Families should not substitute experimental intranasal CBD formulations for approved antiseizure treatment, but researchers should prioritize carefully monitored pediatric pharmacokinetic, safety, and efficacy trials. Primary Analysis | Nanostructured lipid carriers for intran **Study Overview:** Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are severe developmental epileptic encephalopathies that appear in early childhood, are unresponsive to medications, and have a dismal neurodevelopmental prognosis. Most patients do not respond well to polytherapy, and the need to fulfill this gap in clinical practice is urgent. Cannabidiol (CBD) has proven to be an effective adjunct drug, but oral preparations have low bioavailability, slow onset and systemic adverse effects. Nanostructured lipid carriers (NLCs) are an innovative therapeutic technology that can deliver CBD directly to the brain via the nose, enhance brain targeting, achieve faster onset, and minimize systemic exposure, which could be a valuable solution to current deficiencies in treatment. Intranasal NLC-CBD has preclinical evidence of increasing brain CBD levels, facilitating anticonvulsant action, and protecting against seizures in established animal models, like pentylenetetrazol-induced convulsions. NLC-based preparations have increased brain-to-plasma ratios and longer central exposure at lower doses in comparison to free or orally administered CBD. Despite these promising findings, there are still translational gaps to be addressed, such as insufficient safety data in the long term, disease-specific DS/LGS genetic models, inconsistencies in the pediatric nasal physiology, and conventional clinical dosing paradigms. Literature for this review was identified through searches of PubMed, Scopus, Web of Science, and Google Scholar, covering studies published up to March 2026 on CBD, NLC, intranasal drug delivery, DS, and LGS.There is a dire need to carry out properly designed clinical trials that would demonstrate the safety, pharmacokinetics (PK) and efficacy of intranasal NLC-CBD in DS and LGS. The first pediatric clinical trials, adaptive trial models and regulatory harmonization are necessary to convert this noble nanomedicine approach into a clinical therapy. Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare and severe forms of epilepsy which often start in childhood. A significant number of patients fail to respond to several antiseizure drugs, and have recurrent seizures. Cannabidiol (CBD) is a chemical found in the cannabis plant that is effective in reducing seizures, but there are some limitations in oral CBD products, including slow absorption and inconsistent efficacy and the possibility for drug interaction. In this review, a novel delivery system of delivering CBD to the brain via a nose spray containing nanostructured lipid carriers (NLCs) is investigated. The use of these tiny lipid-based particles can aid in the delivery of CBD to the brain more rapidly and effectively, avoiding the digestion process and lowering first-pass metabolism. Consequently, intranasal NLC-CBD is likely to have a quicker onset of effect, better brain penetration, and reduced doses. This review provides a summary of existing preclinical evidence, as well as safety and regulatory considerations and outlines the possible clinical development options for this technology. It also underscores some of the future possibilities, such as the application of artificial intelligence (AI), novel clinical trial designs, and combination therapies. While additional clinical trials are necessary, intranasal NLC-CBD is a promising approach for better seizure control, quality of life and treatment ease for DS and LGS patients and their caregivers. **Primary Source & Scope:** Published in *Therapeutic delivery* (2026Sep17) conducted by Yashika, Sachin Yadav, Anish Arora, Nisha Bharti et al. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42751849/) | **Primary Record:** DOI: 10.1080/20415990.2026.2731738 | PMID: 42751849 How Strong Is This Evidence? The evidence base described here is appropriate for hypothesis generation and formulation development, not for clinical prescribing. Its strength lies in converging preclinical pharmacokinetic and anticonvulsant signals, including brain targeting and animal seizure-model effects. Its weakness is the absence of randomized pediatric clinical data, syndrome-specific efficacy endpoints, and long-term safety follow-up. Where This Paper Deserves Skepticism Animal seizure models, including pentylenetetrazol-induced convulsions, do not fully recapitulate Dravet or Lennox-Gastaut biology, genetics, developmental course, or polytherapy context. A narrative review is also vulnerable to publication bias and heterogeneity across formulations, particle characteristics, dosing methods, and outcome measures. Pediatric nasal physiology, real-world administration technique, infection, rhinitis, and chronic mucosal exposure remain major unmeasured confounders. What This Paper Does Not Show This paper does not show that intranasal NLC-CBD reduces seizure frequency, improves development, or improves quality of life in children with Dravet syndrome or Lennox-Gastaut syndrome. It also does not establish an approved dose, a regulatory pathway outcome, product interchangeability with oral CBD, or long-term pediatric safety. How This Fits With the Broader Clinical Conversation Clinical research into Nanostructured lipid carriers for intranasal canna is progressing through rigorously documented peer-reviewed cohorts. Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries. Dr. Caplan’s Take *The clinical need is unquestionably real. Dravet syndrome and Lennox-Gastaut syndrome are among the most difficult pediatric epilepsies we manage, and families often live with daily uncertainty despite polytherapy. Oral pharmaceutical CBD has earned a role because randomized trials showed seizure reduction, but its dosing can be constrained by gastrointestinal tolerability, somnolence, liver enzyme elevation, and drug interactions. A formulation that could deliver CBD more efficiently to the central nervous system while lowering peripheral exposure is worth studying seriously.* *The key clinical discipline is not to let an elegant delivery concept outrun the evidence. Brain-to-plasma ratios and seizure protection in animal models are encouraging, but they do not tell us how a child with DS or LGS will absorb CBD through the nose during chronic use, especially with age-dependent anatomy, nasal illness, concurrent medications, and variable caregiver administration. I would view intranasal NLC-CBD as a legitimate translational candidate, not as a treatment option to recommend outside a properly designed trial.* What a Careful Reader Should Take Away Intranasal NLC-CBD is a credible research direction, not a current substitute for approved epilepsy care. Families and clinicians should support rigorous trials while avoiding unregulated nasal cannabinoid products. Evidence Interpretation Guide Table of Contents - [How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Interpret This Clinical Study Navigating biomedical publications regarding Nanostructured lipid carriers for intranasal requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **Critical Rule**Separate oral CBD evidence from intranasal NLC-CBD evidence, because proof for one formulation does not automatically transfer to another route or carrier system. **Critical Rule**Treat preclinical brain exposure and animal seizure protection as early translational signals, not as validated pediatric DS or LGS clinical efficacy. **Critical Rule**Look for future trials that report pharmacokinetics, nasal tolerability, antiseizure drug interactions, seizure frequency, responder rates, and long-term developmental safety. Key Evaluation Question Does improved CBD brain targeting with nanostructured lipid carriers translate into safer and more effective seizure control in children with DS or LGS? The Patient Question Would any CBD formulation change affect my child’s seizure control, liver monitoring, and interactions with current antiseizure medicines? The Bottom Line This review identifies a promising intranasal CBD delivery technology, but the clinical claim remains unproven until pediatric trials establish dose, safety, pharmacokinetics, and seizure outcomes. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis This review synthesizes preclinical and translational evidence for intranasal nanostructured lipid carrier CBD in Dravet syndrome and Lennox-Gastaut syndrome. The strongest data are not patient outcomes, but pharmacokinetic and seizure-model observations suggesting better brain targeting than free or oral CBD. That distinction matters. Oral pharmaceutical CBD already has randomized trial evidence in DS and LGS, while intranasal NLC-CBD has not yet demonstrated seizure reduction, tolerability, or dosing reliability in children with these syndromes. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayThe paper supports clinical trial development, not immediate clinical adoption. #### Patient Communication For families, the concept is easy to understand: delivering CBD through the nose may bypass digestion and reach the brain faster. But pediatric epilepsy care cannot rely on plausibility alone, especially in children with frequent seizures and complex polytherapy. Clinicians should explain that approved oral CBD and investigational intranasal NLC-CBD are not interchangeable. Product quality, dose delivered, nasal absorption, seizure monitoring, liver enzymes, and drug interactions all remain essential safety issues. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayHope should be encouraged while clearly separating investigational delivery from proven treatment. #### Dosing & Formulations The review suggests that NLC formulations may achieve higher brain exposure at lower CBD doses than free CBD or oral administration in preclinical models. That could eventually change dose frequency, onset expectations, and systemic adverse effect burden. Still, no pediatric intranasal dose range is established for DS or LGS. Nasal volume limits, mucociliary clearance, age-dependent nasal anatomy, excipient tolerability, and device performance make simple conversion from oral milligrams per kilogram inappropriate. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayIntranasal CBD dosing must be built from human pharmacokinetics, not guessed from oral labels. #### Safety & Side Effect Profile A central promise of intranasal NLC-CBD is reduced systemic exposure, which could theoretically lessen diarrhea, somnolence, appetite effects, hepatic enzyme elevations, and drug interactions. The review frames this as a major rationale for development. The unanswered safety questions are substantial. Children may require chronic use for years, so local nasal irritation, olfactory effects, developmental exposure, immune responses to lipid carriers, and interaction with antiseizure medications need formal study. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayLower systemic exposure is plausible, but long-term pediatric safety remains unproven. #### Regulatory & Policy Dynamics Regulators will not evaluate intranasal NLC-CBD as merely another CBD product. It is a new drug-device-formulation pathway, likely requiring chemistry, manufacturing, stability, nasal toxicology, pharmacokinetics, and pediatric epilepsy efficacy data. Access also depends on quality control. Nonprescription nasal cannabinoid products would be especially concerning because sterility, particle size, excipient safety, dose uniformity, and contamination risks are central to this route of administration. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayThis technology needs pharmaceutical-grade regulation before pediatric epilepsy use. for patients, families, and healthcare providers across all clinical communities. #### Mechanisms & Physiology Intranasal delivery may reach the central nervous system through olfactory and trigeminal pathways, while nanostructured lipid carriers can improve solubility, protect CBD, and alter distribution. These mechanisms are biologically plausible for a lipophilic compound. CBD itself has complex antiseizure pharmacology, including modulation of neuronal excitability, inflammatory signaling, calcium dynamics, and endocannabinoid tone. Better brain delivery could matter, but seizure syndromes are network disorders, not simple drug-level problems. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayMechanistic plausibility is encouraging, but clinical seizure control must be measured directly. #### Research Limitations The key limitation is that the review bridges several evidence domains rather than presenting a completed clinical trial. Animal pentylenetetrazol models and brain-to-plasma ratios do not equal validated DS or LGS outcomes. Important gaps include disease-specific genetic models, pediatric nasal physiology, chronic dosing toxicology, developmental follow-up, and interaction studies with clobazam, valproate, stiripentol, fenfluramine, ketogenic therapy, and other common antiseizure strategies. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayThe strongest unanswered question is whether promising delivery metrics improve real seizures. #### Future Outlook The next rational step is not broad clinical use, but staged translation: adult safety work where appropriate, pediatric nasal tolerability, pharmacokinetics, dose escalation, then syndrome-specific randomized trials with seizure diaries and caregiver-relevant outcomes. If intranasal NLC-CBD proves safe and reliably absorbed, it could become valuable for patients limited by oral tolerability or delayed onset. Until then, it remains a sophisticated hypothesis awaiting human validation. Continuous monitoring of real-world outcomes and transparent communication among stakeholders ensures that clinical practice evolves alongside administrative guidelines. Lens takeawayThe future is promising only if rigorous pediatric trials confirm benefit and safety. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Intranasal+lipid+carrier+cannabidiol+for+Dravet+and+Lennox-Gastaut+syndromes+remains+promising+but+unproven&url=https%3A%2F%2Fcedclinic.com%2Fced-intranasal-lipid-carrier-cannabidio-2026-09-21%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-intranasal-lipid-carrier-cannabidio-2026-09-21%2F) [BlueSky](https://bsky.app/intent/compose?text=Intranasal+lipid+carrier+cannabidiol+for+Dravet+and+Lennox-Gastaut+syndromes+remains+promising+but+unproven%20https%3A%2F%2Fcedclinic.com%2Fced-intranasal-lipid-carrier-cannabidio-2026-09-21%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: Nanostructured lipid carriers for intranasal cannabidiol delivery in Dravet and Lennox-Gastaut syndromes: bridging preclinical promise to clinical translation.](https://pubmed.ncbi.nlm.nih.gov/42751849/) Related Reading at CED ClinicContinue exploring the evidence[CED Clinic Medical Cannabis Education](https://cedclinic.com/about-us/education/) Explore clinical guides, dosing frameworks, and patient resources from Dr. Caplan. [Read Clinical Resources](https://cedclinic.com/about-us/education/)[Understanding Cannabis Dosing and Ratios](https://cedclinic.com/topic-dosage/) A clinical overview of cannabinoid titration and administration methods for patient care. [View Dosing Guide](https://cedclinic.com/topic-dosage/)[Latest Medical Science and Research Reviews](https://cedclinic.com/category/cannabis-science/) Browse CED Clinic’s archive of peer-reviewed study deep dives. [Browse Science Archive](https://cedclinic.com/category/cannabis-science/) ## Frequently Asked Questions Is intranasal NLC-CBD approved for Dravet syndrome or Lennox-Gastaut syndrome? No. This review discusses a proposed delivery strategy supported mainly by preclinical evidence. Approved oral pharmaceutical CBD has evidence and regulatory pathways for these syndromes, but intranasal nanostructured lipid carrier CBD has not yet been proven or approved for pediatric DS or LGS treatment. How is intranasal NLC-CBD different from oral CBD? Oral CBD is swallowed, absorbed through the gut, and undergoes hepatic first-pass metabolism. Intranasal NLC-CBD is designed to deliver CBD through nasal pathways, potentially improving brain targeting and reducing systemic exposure, but this remains a research hypothesis until human pharmacokinetic and clinical outcome data are available. Could this work faster than oral CBD? Possibly, based on the route and preclinical delivery rationale. Intranasal administration can sometimes produce faster absorption than oral dosing, and NLCs may support brain targeting. However, onset time has not been clinically established for children with Dravet or Lennox-Gastaut syndromes. Does this review prove that intranasal CBD reduces seizures in children? No. The review summarizes preclinical seizure-model and pharmacokinetic evidence, but it does not report completed pediatric DS or LGS trials showing seizure reduction, responder rates, rescue medication reduction, or improved quality of life. Could families try making a CBD nasal spray at home? They should not. Nasal delivery requires strict control of sterility, formulation chemistry, particle size, pH, osmolality, preservatives, and dose uniformity. Homemade or retail cannabinoid nasal products could irritate tissue, deliver unpredictable doses, or introduce contaminants. Would intranasal NLC-CBD avoid drug interactions? Not necessarily. Reduced systemic exposure could theoretically lower interaction risk, but CBD can still affect liver enzymes and antiseizure medication levels if enough reaches the bloodstream. Interaction studies with clobazam, valproate, and other drugs are still needed. What safety issues are most important in children? Key concerns include nasal irritation, smell changes, local inflammation, chronic mucosal exposure, systemic CBD effects, liver enzyme changes, sedation, developmental effects, and interactions with existing antiseizure medications. Pediatric long-term safety must be studied directly. Why focus on Dravet and Lennox-Gastaut syndromes? Both are severe developmental epileptic encephalopathies that often begin early in life and remain difficult to control despite multiple medications. Oral CBD already has clinical relevance in these syndromes, making improved CBD delivery a logical research target. What would a convincing clinical trial need to measure? A useful trial should measure pharmacokinetics, nasal tolerability, liver enzymes, antiseizure drug levels, seizure frequency, responder rates, adverse events, caregiver burden, rescue medication use, and quality of life. Randomization and syndrome-specific enrollment would strengthen interpretation. Should current oral CBD patients switch if an intranasal product becomes available experimentally? Any switch should occur only in a supervised research protocol or under specialist guidance. Oral CBD dosing, seizure control, concomitant medication levels, and liver function are clinically sensitive, and abrupt formulation changes can destabilize seizure management. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).